Granata Bio Acquires Oviva Therapeutics, Inc. to Advance Women's Health Solutions

Granata Bio has completed the acquisition of Oviva Therapeutics, Inc., a leading women's health biotech company focusing on treatments for female physiology and ovarian aging. The acquisition emphasizes the potential of Oviva's lead candidate, OVI-586, in extending women's health span by preserving ovarian function and its applications in menopause, contraception, and in vitro fertilization.